Search

Harmony Biosciences Holdings Inc

Abierto

SectorSanidad

38.01 -0.71

Resumen

Variación precio

24h

Actual

Mínimo

37.85

Máximo

38.82

Métricas clave

By Trading Economics

Ingresos

43M

75M

Ventas

46M

261M

P/B

Media del Sector

12.42

57.002

BPA

1.28

Margen de beneficios

28.87

Empleados

293

EBITDA

47M

96M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+8.13% upside

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

210M

2.3B

Apertura anterior

38.72

Cierre anterior

38.01

Noticias sobre sentimiento de mercado

By Acuity

80%

20%

313 / 340 Clasificación en Healthcare

Harmony Biosciences Holdings Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 ago 2026, 22:51 UTC

Harmony Biosciences shares are rising in after-market trading, supported by favorable macroeconomic indicators and a broader trend in major averages closing higher.

11 ago 2026, 19:21 UTC

Harmony Biosciences Holdings Inc. is trading higher today, continuing its upward trajectory since Monday's close amid broader market trends and rising oil prices.

10 ago 2026, 19:46 UTC

Harmony Biosciences Holdings Inc is trading higher, continuing its upward trend since Friday. The stock remains above its 20-day moving average.

7 ago 2026, 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

6 ago 2026, 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5 ago 2026, 20:03 UTC

Social Media
Event
News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4 ago 2026, 20:04 UTC

Social Media
News
Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3 ago 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1 ago 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 jul 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 jul 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 jul 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 jul 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 jul 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 jul 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Comparación entre iguales

Cambio de precio

Harmony Biosciences Holdings Inc previsión

Precio Objetivo

By TipRanks

8.13% repunte

Estimación a 12 Meses

Media 41.63 USD  8.13%

Máximo 55 USD

Mínimo 30 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Harmony Biosciences Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

8 ratings

3

Comprar

4

Mantener

1

Vender

Sentimiento

By Acuity

313 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat